HOLON, Israel, May 2, 2022
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage
cancer immunotherapy company and a pioneer in computational target
discovery, announced today that the Company will release its first
quarter 2022 financial results on Monday,
May 16, 2022, before the U.S. financial markets open.
Management will not host a conference call to accompany this
release.
Management plans to provide a corporate update at two global
investor healthcare conferences in June
2022. Details of the planned presentations will be provided
closer to the events.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody, for the treatment of solid tumors, in Phase 1 as a
single agent and in dual, and triple combinations;
COM902, a potential best-in-class monoclonal antibody
targeting TIGIT for the treatment of solid and hematological
tumors, undergoing Phase 1 studies as a single agent and in dual
combination with COM701. Partnered programs include bapotulimab an
antibody targeting ILDR2 in Phase 1 development, licensed to Bayer
under a research and discovery collaboration and license agreement,
and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase
1/2 development by AstraZeneca through a license agreement for the
development of bispecific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance,
including myeloid targets. Compugen is headquartered in
Israel, with offices in South San
Francisco, CA. Compugen's shares are listed on Nasdaq and
the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, statements regarding
our plans to provide a corporate update at two global investor
healthcare conferences in June 2022
and that details of the planned presentations will be provided
closer to the events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance, or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Investor Relations contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications Compugen
Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2022-on-monday-may-16-2022-301536986.html
SOURCE Compugen Ltd.